At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
NRXP NRX Pharmaceuticals Inc.
Post-Market Trading 11-05 16:23:40 EST
1.27
-0.05
-3.79%
盘后1.27
+0.000.00%
16:00 EST
High1.35
Low1.27
Vol72.39K
Open1.32
D1 Closing1.32
Amplitude6.06%
Mkt Cap13.57M
Tradable Cap9.95M
Total Shares10.68M
T/O93.73K
T/O Rate0.92%
Tradable Shares7.83M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
NRx Pharmaceuticals added to Emerging Growth Conference 76 on October 31 and Update to Schedule
BRIEF-Hope Therapeutics, Inc. And NRX Pharmaceuticals, Inc. Announce Signing Of A Letter Of Intent To Acquire Its First Florida Interventional Psychiatry Clinics
Hope Therapeutics, Inc. and NRX Pharmaceuticals, Inc. (Nasdaq:Nrxp) Announce Signing of a Letter of Intent to Acquire Its First Florida Interventional Psychiatry Clinics
HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) Announce Signing of a Letter of Intent to Acquire its First Florida Interventional Psychiatry Clinics
Hope Therapeutics, Inc. and NRX Pharmaceuticals, Inc. (Nasdaq:Nrxp) Announce Signing of a Letter of Intent to Acquire a Premier West Coast Interventional Psychiatric Clinic
HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) Announce Signing of a Letter of Intent to Acquire a Premier West Coast Interventional Psychiatric Clinic
NRX Pharmaceuticals, Inc. (Nasdaq:Nrxp) Announces Completion of Twelve Months of Stability on the First Manufactured Commercial Scale Lot of NRX-100 (Ketamine)
NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) Announces Completion of Twelve Months of Stability on the First Manufactured Commercial Scale Lot of NRX-100 (Ketamine)
NRx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics based on N-methyl-D-aspartate platform for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned FDA-designated investigational breakthrough therapy for suicidal treatment-resistant bipolar depression and chronic pain; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of acute suicidality in depression. The company has a partnership with Alvogen and Lotus to develop and commercialize NRX-101 for the suicidal bipolar depression treatment, as well as an agreement with Nephron Pharmaceuticals, Inc. to develop ketamine. The company was founded in 2015 and is based in Wilmington, Delaware.